A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

I attended my high school reunion and had no anxiety about appearance,” Sarah gushed. “My new problem was graciously ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...